NEWS
Targeted Drug Benefits Some Patients with Advanced Lung Cancer
The drug crizotinib (Xalkori) substantially lengthens the amount of time some patients with advanced lung cancer live without their disease progressing, according to findings from the first large clinical trial to test the targeted therapy.
Initial results from the trial were presented Sunday at the European Society for Medical Oncology Congress (ESMO) in Vienna, Austria. Read more > >
Drug Combination More Effective than Single Drug for Advanced Melanoma
Targeting two parts of a cell signaling pathway slows disease progressionHealth Care Costs a Major Barrier for Young Adult Cancer Survivors
Financial concerns cause many younger cancer survivors to forgo routine medical careMany Women whose Tumors Disappear after Chemotherapy Have Mastectomies
Response to preoperative chemotherapy may not influence type of breast-cancer surgery
COMMENTARY
![HHS Secretary Kathleen Sebelius](https://webarchive.library.unt.edu/web/20121014002804im_/http://www.cancer.gov/PublishedContent/Images/ncicancerbulletin/100212/GC-home.jpg)
Statement from HHS Secretary Kathleen Sebelius on Breast Cancer Awareness Month
The Honorable Kathleen Sebelius is the 21st secretary of the Department of Health and Human Services, which includes NCI. In a statement marking Breast Cancer Awareness Month, Secretary Sebelius highlights some of the successes and challenges in the fight against the disease while stressing the importance of prevention and early detection.
MULTIMEDIA
NIH Research Radio: Building a Biobank
In the first segment of a series being featured on NIH Research Radio, NCI Cancer Bulletin writer Edward R. Winstead talks about his recent story on the Genotype-Tissue Expression project.Type: (MP3) | Time 5:39 | Size: 3.23 MB | Read Transcipt
IN DEPTH
Turning Genes Up, Not On: A New View of the Myc Protein
Myc may increase the expression of all active genes in a cellWith CellMiner, Researchers Prospect for Cancer Discoveries
Web-based application gives researchers access to storehouse of dataNew Tools Enhance Molecular Portraits of Breast Cancers
TCGA study uses multiple technologies to profile hundreds of tumorsFeatured Clinical Trial: Comparing Radiation Therapy Regimens for Early-Stage Breast Cancer
Will a shorter course of postsurgical radiation therapy be safe and effective for women with breast cancer?
UPDATES
Legislative Update
- President Signs 6-Month Spending Bill
- Congressional Caucus Holds Childhood Cancer Summit
FDA Update
- FDA Approves Ultrasound Imaging System for Dense Breast Tissue
- New Treatment for Advanced Colorectal Cancer Approved
Notes
Selected articles from past issues of the NCI Cancer Bulletin are available in Spanish.
The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI), which was established in 1937. Through basic, clinical, and population-based biomedical research and training, NCI conducts and supports research that will lead to a future in which we can identify the environmental and genetic causes of cancer, prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.
For more information about cancer, call 1-800-4-CANCER or visit http://www.cancer.gov.
NCI Cancer Bulletin staff can be reached at ncicancerbulletin@mail.nih.gov.